OncoSec Medical Announces Positive Interim Data from Phase 2 Metastatic Melanoma Study
December 16, 2013 at 06:07 AM EST
OncoSec Medical (OTC: ONCS ) today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal…